Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

BioStratum, CRN Spar Over Pyridoxamine’s Pre-DSHEA Marketing Status

This article was originally published in The Tan Sheet

Executive Summary

BioStratum insists there is no evidence supporting the Council for Responsible Nutrition's claim that pyridoxamine was sold as a dietary ingredient before 1994 and says the ingredient should not be considered "grandfathered" under DSHEA

You may also be interested in...



FDA Dismisses List Of “Grandfathered” Ingredients In Pyridoxamine Decision

Companies determining whether a substance is a new dietary ingredient cannot rely on industry-developed lists of "grandfathered" ingredients believed to be marketed prior to the Dietary Supplement Health and Education Act, FDA says in response to a citizen petition

FDA Dismisses List Of “Grandfathered” Ingredients In Pyridoxamine Decision

Companies determining whether a substance is a new dietary ingredient cannot rely on industry-developed lists of "grandfathered" ingredients believed to be marketed prior to the Dietary Supplement Health and Education Act, FDA says in response to a citizen petition

FDA Dismisses List Of “Grandfathered” Ingredients In Pyridoxamine Decision

Companies determining whether a substance is a new dietary ingredient cannot rely on industry-developed lists of "grandfathered" ingredients believed to be marketed prior to the Dietary Supplement Health and Education Act, FDA says in response to a citizen petition

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS098747

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel